Recursion Pharmaceuticals, Inc. (RXRX) Misses Q1 EPS by 1c

Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) reported Q1 EPS of ($0.50), $0.01 worse than the analyst estimate of ($0.49). Revenue for the quarter came in at $14.75 million versus the consensus estimate of $14.98 million.

For earnings history and earnings-related data on Recursion Pharmaceuticals, Inc. (RXRX) click here.

You May Also Be Interested In

• Mosaic (MOS), Others Lower Following Trump Post on Potash from Belarus
• RBC Capital Upgrades Telix Pharmaceuticals Ltd (TLX:AU) (TLX) to Outperform
• Lumentum shares climb on optical AI demo with Qualcomm